To date, only endothelin receptor antagonists (ERA), which block both ETAR and ETBR, have been successfully used to treat vasculopathic manifestations in SSc, such as PAH and DUs [86,87]. The gene discussed is EDNRB; the disease is pulmonary arterial hypertension.